Vancouver, BC-based drug development company Algernon Pharmaceuticals has entered an agreement to acquire 100% of the issued and outstanding shares of NoBrainer Imaging Centers.
The acquisition will move Algernon into the Alzheimer’s disease diagnostic and treatment market and provide the company with exclusive master franchise and licensing rights to open Alzheimer’s disease screening, diagnostic, and treatment centers across Canada and in multiple U.S. markets.
Algernon plans to establish company-owned clinics and sell individual franchise licenses, allowing for rapid expansion throughout Canada, Florida, and Los Angeles, as well as in five strategic cities in other American states, the company said.
The clinics will be anchored by Positrigo’s dedicated brain PET imaging system, NeuroLF, which received U.S. clearance in 2024, Algernon added.
